Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

You may be eligible if

• Disease Characteristics:
• Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma
• Measurable lesion diagnosed by CT scan
• Recurrent/metastatic disease considered surgically unresectable.
• Prior/Concurrent Therapy:
• Chemotherapy: Patients who either have failed at least one regimen of standard systemic therapy, or are clinically asymptomatic and are not presently being considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last treatment)
• Other: Prior treatment with investigational agents is excluded unless follow-up is completed and patient is off study
• Performance Status: Patients with a Karnofsky performance status \> 70% (or equivalent, ECOG 0-1) and expected survival of at least 3 months.
• Hematopoietic: WBC \>/= 3000 mm3, neutrophils \>/= 1500 mm3, platelets \>/= 75,000, CEA \< 300 ng/mL
• Hepatic: Serum bilirubin \</= 2.0 mg/dL, ALT \< 2.5 x IULN
• Cardiovascular: Patients with LVEF \>/= 40% by required MUGA/2D-ECHO study.
• Pulmonary: Patients with FEV1 \>/= 60% by required Pulmonary Function Tests
• Other: Patients agreeing to use a medically effective method of contraception during and for a period of 3 months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent. Patients with a significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.